PDS Biotech (NASDAQ: $PDSB) is focused on the development & commercialization of T-cell stimulating immunotherapies based on the Versamune® platform.
Princeton, NJ
- Tweets 538
- Following 103
- Followers 1,953
- Likes 55
Data recently published in JAMA Oncology from a Phase 2 trial of PDS0101 showed a median overall survival of 39.3 months in first-line (1L), recurrent/metastatic (R/M), immune checkpoint inhibitor (ICI)-naïve patients. Read more about the results: bit.ly/3T3cP1f $PDSB
3
13
980
Kirk Shepard, M.D., PDS Biotech Chief Medical Officer, comments on the publication of VERSATILE-002 Ph.2 clinical trial results in JAMA Oncology, evaluating PDS0101 in combination with pembrolizumab in HPV16-positive R/M head and neck cancer: bit.ly/4yrViPP $PDSB
4
586
Results from a Phase 2 trial of $PDSB’s HPV16-targeted immunotherapy PDS0101 in combination with pembrolizumab were recently published in JAMA Oncology. PDS Biotech continues to prioritize PDS0301 in mCRC while pursuing a partnership strategy for PDS0101. bit.ly/4yrViPP
3
1
16
2,446
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors: bit.ly/4dzHKJi $PDSB
1
9
1,080
PDS Biotech announces up to $22.55M in equity funding in a PIPE transaction. In connection, Dr. Patrick Soon-Shiong, M.D., will join $PDSB's Board. The Company expects the PIPE will advance development of PDS0301 into late-stage clinical development. bit.ly/4xJ7v29
2
5
16
4,485
PDS Biotech Reports Second Quarter 2026 Financial Results: bit.ly/4cDCrrP $PDSB
6
2
1,694
PDS Biotech has announced a strategic refocus prioritizing the advancement of PDS0301 in metastatic colorectal cancer (mCRC) while pursing strategic partnership opportunities for PDS0101. Read the Letter to Shareholders from CEO Frank Bedu-Addo, Ph.D.: bit.ly/4i0MDOC $PDSB
12
3
4,427
PDS Biotech will host a conference call and webcast today at 8:00 am ET to report financial results for the quarter and year ended March 31, 2026, and provide a clinical programs and corporate update. Join the webcast here: bit.ly/4wf8Gpo $PDSB
1
2
5
1,646
Frank Bedu-Addo, PhD, President and CEO of PDS Biotech, comments on the clinical and regulatory progress made in the first quarter 2026: bit.ly/4uCFTtw $PDSB
1
1
7
1,994
PDS Biotech today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026. Read more: bit.ly/4uCFTtw $PDSB
5
1,741
PDS Biotech will host a conference call and webcast to report financial results for the quarter ended March 31, 2026, and provide a clinical programs and corporate update, on Wednesday, May 13, 2026 at 8:00 am ET. For details: bit.ly/4f5ulu4 $PDSB
1
2
1,218
April is #HeadAndNeckCancerAwarenessMonth. HPV is fueling a rise in these cancers, and patients deserve better treatment options. At PDS Biotech, we are seeking to deliver a novel and promising targeted immunotherapy for HPV16-driven head and neck cancers. Learn more: bit.ly/3X0FUsN
1
4
1,090
Head and neck cancers are expected to impact nearly 73,000 Americans this year, according to @theNCI. Early detection can save lives. Learn more about how to spot the symptoms from @CDCgov: bit.ly/3Ouls2k #HeadAndNeckCancerAwarenessMonth
7
1,112
Trials of PDS01ADC were performed in unresectable MSS or pMMR colorectal liver metasteses, which constitute the majority of mCRC, and in which immune checkpoint inhibitors have been unsuccessful. Read more on our positive Stage 1 interim Ph. 2 data: bit.ly/4ceHUWA $PDSB
1
3
11
1,518
PDS Biotech CEO Frank Bedu-Addo, PhD. comments on the positive PDS01ADC interim Phase 2 clinical trial data from Stage 1 of NCI-led metastatic colorectal cancer (mCRC) trial: bit.ly/4ceHUWA $PDSB
1
1
9
931
Recently published data in the Journal of Clinical Oncology (JCO) Oncology Advances highlights PDS01ADC's 78% objective response rate (ORR) and 2-year survival rate of >80%. Read more: bit.ly/4ceHUWA $PDSB
1
7
1,295
PDS Biotech today announced the publication of clinical and immunological biomarker data from Stage 1 of a Phase 2 trial evaluating its tumor-targeted IL-12 immunocytokine, PDS01ADC, in the March 10, 2026 issue of JCO Oncology Advances. Read more: bit.ly/4ceHUWA $PDSB
2
3
12
1,832
"The fourth quarter capped a year of important progress for PDS Biotech, marked by meaningful advances across our clinical programs, financial discipline, and intellectual property portfolio," said Frank Bedu-Addo, PhD, President and CEO. Read more: bit.ly/47vWE0o] $PDSB
2
6
2,225
PDS Biotech today provided a business and clinical programs update and reported financial results for the quarter and year ended December 31, 2025. Read the full clinical and corporate update: bit.ly/47vWE0o $PDSB
1
1
1,804
PDS Biotech will host a conference call and webcast today at 8:00 am ET to report financial results for the quarter and year ended December 31, 2025, and provide a clinical programs and corporate update. Join the webcast here: bit.ly/4uPPzl5 $PDSB
1
616